The serine/threonine kinase Akt (also known as protein kinase B, PKB) is activated by numerous growth-factor and immune receptors through lipid products of phosphatidylinositol (PI) 3-kinase. Akt can couple to pathways that regulate glucose metabolism or cell survival [1] . Akt can also regulate several transcription factors, including E2F, CREB, and the Forkhead family member Daf-16 [2-4]. Here, we show that Akt can regulate signaling pathways that lead to induction of the NF-κ κB family of transcription factors in the Jurkat T-cell line. This induction occurs, at least in part, at the level of degradation of the NF-κ κB inhibitor Iκ κB, and is specific for NF-κ κB, as other inducible transcription factors are not affected by Akt overexpression. Furthermore, the effect requires the kinase activity and pleckstrin homology (PH) domain of Akt. Also, Akt does not act alone to induce cytokine promoters and NF-κ κB reporters, because signals from other pathways are required to observe the effect. These studies uncover a previously unappreciated connection between Akt and NF-κ κB induction that could have implications for the control of T-cell growth and survival. 
Results and discussion
The promoter of the interleukin-2 (IL-2) gene has provided a model system with which to study signals downstream of the T-cell receptor (TCR) and the CD28 co-stimulatory receptor [5] [6] [7] . To investigate the potential role of Akt in T-cell activation, Jurkat T cells were cotransfected with an expression vector encoding Akt and a reporter plasmid containing the luciferase gene driven by the IL-2 promoter. Overexpression of Akt in Jurkat cells led to a 7-10-fold increase in IL-2 promoter activity over that obtained by stimulation with phorbol myristate acetate (PMA) and ionomycin alone ( Figure 1a ). Intriguingly, the effect is similar to that seen when CD28 (but not the TCR) is crosslinked in conjunction with the submaximal stimulus of PMA and ionomycin (data not shown; [6] ). Overexpression of Akt had no effect on the basal level of IL-2 promoter activity (data not shown).
The IL-2 promoter contains a number of binding sites for transcription factors, including sites for NFAT, AP-1, NF-κB, and a CD28-responsive element/AP-1 composite site (termed RE/AP) [6, 8] . Reporter plasmids containing individual binding sites from the IL-2 promoter were assayed using soluble anti-TCR antibody and PMA as stimuli, as they provide an efficient but sub-maximal stimulus. Little if any effect of Akt overexpression was seen on luciferase reporter plasmids driven by AP-1-or NFATbinding sites (Figure 1a ), but when a reporter driven by the NF-κB consensus site from the human immunodeficiency virus long terminal repeat (HIV LTR) or the RE/AP-binding site from the IL-2 promoter was examined, a dramatic potentiation was noted upon Akt overexpression. As with the IL-2 promoter, Akt overexpression did not affect the basal level of transcription from any of these individual elements (data not shown). Akt was expressed at comparable levels in all transfections (Figure 1a , inset). The selective enhancement by Akt of NF-κB and RE/AP reporters suggested that Akt was specifically influencing NF-κB induction. The consequences of Akt overexpression for other NF-κB-dependent reporter plasmids were investigated. Only certain responses of reporters driven by NF-κB elements from the major histocompatibility complex (MHC) class I promoter (Figure 1b) , the RE/AP site (see above) or the IL-2 receptor α chain promoter (data not shown) were strongly augmented by Akt. The effect of Akt was most striking in conjunction with a low concentration of PMA.
The NF-κB reporter assays were repeated with various mutants of Akt. An inactivating mutation of the kinase domain or deletion of the PH domain prevented Akt from potentiating NF-κB-dependent transcription (Figure 2a) . A myristylated version of Akt, which is targeted to the plasma membrane and is constitutively active, was also capable of increasing transcription from NF-κB-binding sites. Thus, Akt augmentation of NF-κB activity requires Akt kinase activity and the Akt PH domain.
As Akt is activated in part by products of PI 3-kinase, we determined whether the effect of Akt on NF-κB induction was dependent upon cellular PI 3-kinase activity, using the PI 3-kinase inhibitors LY294002 and wortmannin [9, 10] . Both LY294002 (Figure 2b ) and wortmannin (data not shown) could effectively inhibit the potentiation of RE/AP reporter (or NF-κB reporter; data not shown) activity by wild-type Akt in the presence of PMA, demonstrating that endogenous PI 3-kinase activity is required.
The inhibitors did not block induction of reporter activity by PMA and myristylated Akt (Figure 2b and data not shown), however, consistent with reports that membranetargeted Akt is partially PI 3-kinase independent [1, 11, 12] . An activated, membrane-targeted form of PI 3-kinase, p110-CAAX [13] , potentiated the induction of NF-κB activity by Akt and PMA (Figure 2c ), but did not affect RE/AP or NF-κB activity in the absence of Akt expression, with or without PMA (Figure 2c and data not shown). Thus, although PI 3-kinase activity is required for NF-κB induction by Akt, PI 3-kinase overexpression alone is not capable of mediating such an effect. However, other potential targets of p110 include proteins such as Itk, Vav, and phospholipase Cγ [14] [15] [16] .
We examined whether stimulation of Jurkat cells with PMA and Akt resulted in increased nuclear levels of NF-κB proteins that could bind to NF-κB-binding sites. These experiments were conducted with Jurkat cell lines stably expressing myristylated Akt, which mediates stronger NF-κB-mediated transcriptional activation than wild-type Akt in stable cell lines (data not shown). Low levels of nuclear NF-κB-binding factors were seen when a control clone was stimulated with PMA alone, with significantly higher levels when anti-CD28 antibody was also added as a positive control. By contrast, clones expressing myristylated Akt yielded significantly higher nuclear levels of NF-κB-binding complexes. These results suggest that the strong transcriptional upregulation by Akt is due, at least in part, to increased NF-κB levels in the nucleus, which would be expected to result from degradation of IκB proteins.
The requirement for IκB degradation in NF-κB activation by Akt was first addressed with a mutant form of IκB-α (IκB-AA) that contains serine-to-alanine mutations of the sites required for phosphorylation and degradation. IκB-AA therefore cannot be phosphorylated and degraded and acts as a potent inhibitor of NF-κB activation [17] . IκB-AA potently inhibited the activation of a NF-κB-driven reporter by various stimuli, including PMA and Akt (Figure 3b ). IκB-AA also inhibited activation of the RE/AP-driven reporter, but not of an NFAT-driven reporter (data not shown). Similar results were seen with MG-132, a proteasome inhibitor which prevents IκB degradation [17] (data not shown). These experiments implicate the involvement of IκB in Akt-mediated NF-κB induction. To examine this more directly, tagged forms of IκB-α and IκB-β were expressed in Jurkat cells, with or without Akt overexpression. The degradation of IκB was then followed, after treatment with PMA and cycloheximide, which was added to prevent NF-κB-mediated IκB re-expression. PMA treatment alone was sufficient to effect moderate to complete degradation of IκB-α, but this occurred more efficiently in cells overexpressing Akt (Figure 3c ). The effect on IκB-β was even more dramatic, in that PMA did not induce significant degradation of IκB-β unless cells overexpressed Akt.
We tested whether known IκB kinases [18] were required for Akt-mediated NF-κB activation. The IκB kinases IKK-α and IKK-β directly phosphorylate IκB-α and IκB-β on the two serine residues that are critical for IκB ubiquitination and degradation. Kinase-deficient IKK-α or IKK-β was co-transfected with Akt. These kinase-deficient forms of IKK-α or IKK-β inhibited the activation of an NF-κB-driven reporter by PMA and Akt, but did not affect Akt expression (Figure 4a ) or transfection efficiency (data not shown). NF-κB-inducing kinase (NIK) has also been implicated in NF-κB activation (reviewed in [18] ). A kinase-deficient form of NIK [19] was transfected into Jurkat cells with Akt and specific inhibition of NF-κB reporter activity was also observed in these cells after stimulation with PMA (Figure 4a) , without a significant effect on expression of Akt or transfection efficiency (data not shown). Finally, the effect of Akt on IKK activation was assessed directly. Empty vector or an Akt expression vector was co-transfected with a vector encoding epitopetagged IKK-α. As shown in Figure 4b , PMA alone (at 10 ng/ml) was unable to activate IKK-α in cells transfected with empty vector, but could activate IKK-α when Akt was overexpressed.
The results presented here are consistent with a model whereby Akt and other signals act upstream of the IKKs in effecting NF-κB induction. Akt may contribute to NF-κB induction by a subset of receptors in T cells, such as the TCR, CD28, or the IL-1 receptor [20] . We are currently investigating whether these or other receptors require Akt activation in order to mediate inducible transcription. We are also interested in identifying the direct target(s) for Akt in the NF-κB pathway. The IKKs, IκBs and NIK do Brief Communication 603 not contain a consensus sequence for phosphorylation by Akt, as defined by Alessi et al. [21] . Akt may therefore lead to IKK activation through a MAPKKK family member other than NIK or, alternatively, Akt may target a previously unknown pathway for IKK activation.
Supplementary material
Additional methodological detail is published with this paper on the internet. 
Supplementary materials and methods

Plasmids
The IL-2 promoter reporter contains 275 bp upstream of the IL-2 transcriptional start site [S1]. NF-κB reporters were from the following sources: HIV, from Jorge Moscat and MHC class I from Albert Baldwin. The IL-2 receptor α NF-κB and IL-2 RE/AP reporters were described previously [S2,S3]. NFAT and AP-1 luciferase reporters have been described previously [S2] . The pCMV4 vectors encoding FLAGtagged IκB-α and IκB-β were from Dean Ballard; kinase-deficient NIK, and IKKs were from Warner Greene; p110-CAAX was from Julian Downward; FLAG-IKK-α was from David Goeddel.
Antibodies and biochemicals
Polyclonal antibodies directed against Akt (C-20) and IκB-β (C-20) were obtained from Santa Cruz Biotechnology. Antiserum specific for IκB-α was from Joseph Didonato. Murine IgM (clone C305) specific for the Jurkat TCR was produced in a Miniperm apparatus and used at a dilution of 1:1,000. Anti-human CD28 ascites (clone 9.3) was obtained from Bristol-Myers Squibb, and used at a 1:2,000 dilution. Anti-FLAG antibody M2 was obtained from Sigma Chemical Co. PMA, cycloheximide, LY294002, and wortmannin were obtained from Calbiochem.
Transfections and luciferase assays
Jurkat cells were transfected by electroporation. Cells grown to a density of 0.5-1.0 × 10 6 per ml were washed into room-temperature, serum-free RPMI at a final density of 3 × 10 7 /ml. Cells (0.4 ml) were added to a 0.4 cm gap cuvette (Invitrogen) containing plasmid DNA, as indicated. Electroporation was carried out at 250 V, 960 µF. Cells were immediately transferred to a small tissue culture plate with 10 ml RPMI containing 5% FCS and cultured for 16-18 h at 37°C, 5% CO 2 . For generation of stable cell lines, cells were plated at various dilutions in 96-well plates, in complete medium containing 2 mg/ml G418. Several weeks later, clones were transferred and expanded. Expression of tagged Akt was confirmed with a polyclonal antiserum specific for Akt.
For luciferase assays, the cells were washed and resuspended at 2 × 10 6 per ml in RPMI containing 5% FCS. Cells were aliquotted into round-bottom 96-well plates (50 µl) with RPMI+FCS containing 2× concentration of the indicated stimuli (50 µl). After 6 h at 37°C, 5% CO 2 , cells were permeabilized with 11 ml luciferase harvest buffer (10% Triton X-100, 1 mM DTT, 0.2 M KPO 4 pH 7.8). After 5 min at room temperature, samples were transferred to an opaque 96-well plate, and 100 µl of luciferase assay buffer was added (10 mM ATP, 20 mM MgCl 2 , 0.2 M KPO 4 pH 7.8). Luciferase activity was determined in a MicroLumat luminometer (EG&G Berthold), with a 10 sec reading, after injection of 50 µl 1 mM luciferin.
Gel shift assays
Before preparation of nuclear extracts, Jurkat cells were treated for 4 h in RPMI+FCS, as indicated. Cells (10 7 ) were pelleted and washed twice with PBS. The final pellet was resuspended in 0.8 ml buffer A (10 mM HEPES-KOH pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) and left on ice for 15 min. NP-40 was added to 0.5% and samples vortexed for 20 sec, then spun for 30 sec at maximum speed. The supernatant was discarded and the pellet washed with 0.5 ml buffer A. The pellet was solubilized with 0.1 ml buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) by gently agitating for 20 min. Samples were spun for 10 min at maximum speed in a microfuge and the supernatants saved and quantitated for protein levels.
Nuclear extracts (6 µg) were mixed with buffer, 32 P-labeled NF-κB probe [S3], and poly(dI-dC) in a final volume of 20 µl. Reactions were incubated for 20 min at room temperature. Half of each reaction was loaded on a 4% acrylamide-TBE gel. Gels were dried and exposed to X-OMAT film for 8-24 h.
SDS-PAGE and western blotting
Whole-cell lysates were prepared by lysing 10 6 cells in lysis buffer (1% NP-40, 150 mM NaCl, 20 mM Tris pH 7.5 + protease inhibitors) at 4 × 10 7 cells/ml. After incubation on ice for 10 min, lysates were spun for 10 min at maximum speed in a microcentrifuge. Post-nuclear supernatants were mixed with 4× reducing sample buffer and boiled for 5 min. Samples were separated on a 10% polyacrylamide gel, which was then transferred to PVDF membrane (Millipore) using a semi-dry blotting apparatus. Blots were blocked with 5% non-fat milk in wash buffer (250 mM NaCl, 20 mM Tris pH 7.5, 0.05% Tween-20) for 2 h at room temperature. Primary antibody was incubated for 1 h at room temperature in wash buffer, followed by three 10 min washes. Horseradishperoxidase-conjugated secondary antibody was diluted to 1:10,000 in wash buffer and incubated with blots for 1 h at room temperature, followed by three 15 min washes, and development by enhanced chemiluminescence (Amersham).
IKK kinase assays
Jurkat T cells were transfected, as above, with FLAG-tagged IKK and indicated additional plasmids. Cells were harvested 20 h later and washed with PBS. A total of 10 7 cells per condition were resuspended in RPMI and stimulated for 20 min at 37°C. Cells were washed once in ice-cold PBS and lysed in 800 µl lysis buffer (1% NP-40, 250 mM NaCl, 1 mM EDTA, 50 mM Hepes pH 7.4) + protease inhibitors. IKK was immunoprecipitated from post-nuclear supernatants with M2 antibody coupled to protein-G beads, with rotation for 2 h. Beads were washed three times with lysis buffer and once with kinase buffer (1 mM MnCl 2 , 5 mM MgCl 2 , 10 mM HEPES pH 7.4) + phosphatase inhibitors. Reactions were carried out for 30 min at 30°C in 20 µl kinase buffer with 1 µg GST-IκB and 5 µCi [γ-32 P]ATP. Reactions were stopped by the addition of SDS sample buffer. Samples were boiled for 5 min, separated by SDS-PAGE and blotted to PVDF. Blots were exposed to film overnight to determine kinase activity, then blocked and probed for IKK levels with a polyclonal IKK antibody. 
Supplementary references
